Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2002
09/19/2002WO2002072098A1 Method of treatment
09/19/2002WO2002072097A1 Remedies and/or preventives for diabetic ischemic heart diseases
09/19/2002WO2002072096A1 Acridines as stimulators for fas-mediated apoptosis
09/19/2002WO2002072095A2 Tiotropium salts for treating inflammatory diseases
09/19/2002WO2002072094A2 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease
09/19/2002WO2002072093A2 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
09/19/2002WO2002072092A1 Method for increasing leptin levels using nicotinic acid compounds
09/19/2002WO2002072091A1 Anticancer drug-tolerance inhibitors
09/19/2002WO2002072090A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
09/19/2002WO2002072089A2 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof
09/19/2002WO2002072088A2 Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
09/19/2002WO2002072086A2 Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
09/19/2002WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
09/19/2002WO2002072084A2 Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
09/19/2002WO2002072083A1 Novel inhibitors of formation of advanced glycation endproducts (ages)
09/19/2002WO2002072082A1 Therapeutic composition for broad spectrum dermal disease
09/19/2002WO2002072081A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same
09/19/2002WO2002072080A2 Paracetamol solutions which are stable in storage and ready for infusion
09/19/2002WO2002072078A2 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications
09/19/2002WO2002072074A1 Method to prepare microparticles metoprolol that contain
09/19/2002WO2002072073A2 Pharmaceutical formulation comprising atorvastatin calcium
09/19/2002WO2002072072A2 Granules and granules coated with a masked taste
09/19/2002WO2002072071A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
09/19/2002WO2002072070A1 Method to obtain microparticles containing a h+, k+-atp-ase inhibitor
09/19/2002WO2002072067A2 Pharmaceutical aerosol formulation
09/19/2002WO2002072066A1 Composition for rectal delivery of an oxazolidinone antibacterial drug
09/19/2002WO2002072065A1 Topical application for treating toenail fungus
09/19/2002WO2002072059A2 Topical composition comprising a functionally alkylating cosmetic bonding agent
09/19/2002WO2002072054A1 Emulsion composition
09/19/2002WO2002072053A1 Use of a mixture designed to reduce secretion of sebum in a cosmetic or dermatological composition
09/19/2002WO2002072051A2 Pharmaceutical and cosmetic compositions for the protection of the skin from damages induced by sun radiations
09/19/2002WO2002072049A1 Medicinal compositions for stimulating hair growth
09/19/2002WO2002072047A2 Cosmetic or pharmaceutical agent
09/19/2002WO2002072041A1 Cosmetics and treatment method for promoting maturation of cornified envelopes
09/19/2002WO2002072039A2 Topical preparations and food preparations comprising a pyridoxine-alpha-d-glucose
09/19/2002WO2002072035A2 Novel anti-inflammatory compositions and methods of use
09/19/2002WO2002072034A2 Chronotherapeutic dosage forms
09/19/2002WO2002072033A2 Chronotherapeutic dosage forms containing glucocorticosteroid
09/19/2002WO2002072031A2 Substituted tetracycline compounds as synergistic antifungal agents
09/19/2002WO2002072029A2 Dopamine d4 receptor antagonists as treatment for attention deficit-hyperactivity disorder
09/19/2002WO2002072025A2 Improving postsynaptic response by a combination of 4-minopyridine and agonist
09/19/2002WO2002072022A2 Substituted tetracycline compounds as antifungal agents
09/19/2002WO2002072021A2 Agents and methods for the prevention of initial onset and recurrence of existing cancers
09/19/2002WO2002072020A2 Novel anti-adhesive compounds and uses thereof
09/19/2002WO2002072018A2 A cream-t0-powder dermatological composition
09/19/2002WO2002072014A2 Medical devices, compositions and methods for treating vulnerable plaque
09/19/2002WO2002072010A2 Taxane prodrugs
09/19/2002WO2002072009A2 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
09/19/2002WO2002072007A2 Facially amphiphilic polymers as anti-infective agents
09/19/2002WO2002072003A2 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour
09/19/2002WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity
09/19/2002WO2002071866A1 Method and product for treating cancer in pets
09/19/2002WO2002071847A1 Treatment of neurodegenerative diseases and conditions using pari antagonists
09/19/2002WO2002071844A1 Heterocyclic hydroxamic acid derivatives as mmp inhibitors
09/19/2002WO2002071827A2 Retinoid x receptor modulators
09/19/2002WO2002059109A3 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases
09/19/2002WO2002058680A3 Use of bicylic amino acids for preventing and treating visceral pain and gastrointestinal disorders
09/19/2002WO2002055519A3 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
09/19/2002WO2002055095A3 Use of aziridino-compounds in the treatment of immune dysfunctions
09/19/2002WO2002053617B1 Linear block polymer
09/19/2002WO2002053533A3 Kappa opioid receptor ligands
09/19/2002WO2002053138A3 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
09/19/2002WO2002050070A3 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
09/19/2002WO2002050028A3 Substituted benzoindoles as spla2 inhibitors
09/19/2002WO2002049624A3 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
09/19/2002WO2002048154A3 Cobalt-porphyrin complexes and use thereof as an anti-obesity agent
09/19/2002WO2002045569A3 Method for precipitating red blood cells
09/19/2002WO2002043685A3 Cosmetic and/or pharmaceutical emulsions
09/19/2002WO2002042311A3 Biotin derivatives, methods for making same and uses thereof as vectors
09/19/2002WO2002039835A9 Indigestible oligosaccharides and magnesium absorption in humans
09/19/2002WO2002038577A3 Extended release erythromycin derivatives
09/19/2002WO2002036123A3 New treatments for restless legs syndrome
09/19/2002WO2002036106A3 Novel medicament compositions based on anticholinergics and corticosteroids
09/19/2002WO2002032919A3 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance
09/19/2002WO2002032374A3 Methods for treating il-18 mediated disorders
09/19/2002WO2002030409A8 Methods for the treatment of a traumatic central nervous system injury
09/19/2002WO2002026730A3 Fluorinated quinolones as antimitotic and antitumor agents
09/19/2002WO2002024695A3 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
09/19/2002WO2002024194A9 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
09/19/2002WO2002024158A3 Pulmonary delivery in treating disorders of the central nervous system
09/19/2002WO2002020841A3 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
09/19/2002WO2002020018A8 Tablets containing epinastine manufactured by direct compression
09/19/2002WO2002017949A9 Novel functions for dp214
09/19/2002WO2002014311A3 Urea compounds and methods of uses
09/19/2002WO2002010382A9 Trp8, trp9 and trp10, markers for cancer
09/19/2002WO2002005792A9 Use of matrix metalloprotease inhibitors for the treatment of cancer
09/19/2002WO2002002189A3 Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections
09/19/2002WO2001097779A3 Improved injectable dispersions of propofol
09/19/2002WO2001093858A3 Use of an aluminium and ethylenediamine-tetraacetic complex for preventing and/or treating urticaria
09/19/2002WO2001090162A9 Crystal structure data of cystalysin and use thereof for the design and preparation of inhibitor molecules
09/19/2002WO2001083514A3 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof
09/19/2002WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors
09/19/2002WO2001070221A1 Sustained release oral preparations
09/19/2002WO2001064949A3 Diagnostics and therapeutics for glaucoma
09/19/2002WO2001063539A8 Anti-infective agents useful against multidrug-resistant strains of bacteria
09/19/2002WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases
09/19/2002WO2001019360A3 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
09/19/2002WO2001016139A9 Androgen receptor modulator compounds and methods
09/19/2002WO2001007020A3 Carboxylic acid amides, medicaments containing these compounds and the use and production thereof
09/19/2002US20020133026 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide